Quest Diagnostics
DGX | NYSE
$262.21
+$2.61 (+1.01%)
At close: Nov 16, 2026, 4:00 PM ET
$261.25
-$0.96 (-0.37%)
After-hours:
Nov 16, 2026, 7:29 PM ET
Quest Diagnostics Company Profile
Company profile explainedCompany Profile
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Key Executives
| Name | Position |
|---|---|
| James E. Davis | Chairman, Chief Executive Officer & President |
| Sam A. Samad | Executive Vice President & Chief Financial Officer |
| Catherine T. Doherty | Executive Vice President of Regional Businesses |
| Damini Chokshi | Vice President of Investor Relations |
| Dan Haemmerle | Interim VP of Investor Relations & VP Finance |
| Garry Clark | Senior Vice President and Chief Marketing & Communications Officer |
| Karthik Kuppusamy | Senior Vice President of Clinical Solutions |
| Kristin Lee Wallace | Senior Vice President & Chief Compliance Officer |
| Michael E. Prevoznik | Senior Vice President & General Counsel |
| Michael J. Deppe | Senior Vice President, Corporate Controller & Chief Accounting Officer |
| Murali Balakumar | Senior Vice President and Chief Information & Digital Officer |
Quest Diagnostics
| Country | United States |
| IPO Date | Dec 17, 1996 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 57,000 |
| CEO | James E. Davis |
Contact Details
500 Plaza Drive Secaucus,
New Jersey 07094 United States
Stock Details
| Ticker Symbol | DGX |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001022079 |
| CUSIP Number | 74834L100 |
| ISIN Number | US74834L1008 |
| SIC Code | 8071 |
Recent News
- 4 days ago / zacks.comHere's Why Quest Diagnostics (DGX) is a Strong Value Stock
- 6 days ago / prnewswire.comQuest Diagnostics Declares Quarterly Cash Dividend
- 21 days ago / zacks.comWhy Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
- 21 days ago / seekingalpha.comQuest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's
- 24 days ago / businesswire.comPRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records
- 25 days ago / techcrunch.comLab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach
- 25 days ago / zacks.comWhy Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
- 26 days ago / zacks.comDGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market
- 26 days ago / marketbeat.comWhat Quest Diagnostics (DGX) Said on Its Q3 Earnings Call
- 26 days ago / fool.comQuest Diagnostics: 3 Key Takeaways for Long-Term Investors
Add to Watchlist
Select watchlists to add or remove DGX